Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Treasury Shares (2023 - 2025)

Historic Treasury Shares for Avidity Biosciences (RNA) over the last 3 years, with Q1 2025 value amounting to $2.6 million.

  • Avidity Biosciences' Treasury Shares rose 8586.57% to $2.6 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.6 million, marking a year-over-year increase of 8586.57%. This contributed to the annual value of $2.1 million for FY2024, which is 17849.6% up from last year.
  • Avidity Biosciences' Treasury Shares amounted to $2.6 million in Q1 2025, which was up 8586.57% from $2.1 million recorded in Q4 2024.
  • In the past 5 years, Avidity Biosciences' Treasury Shares ranged from a high of $2.6 million in Q1 2025 and a low of $607000.0 during Q1 2023
  • Its 3-year average for Treasury Shares is $1.3 million, with a median of $1.4 million in 2024.
  • As far as peak fluctuations go, Avidity Biosciences' Treasury Shares skyrocketed by 17849.6% in 2024, and later soared by 8586.57% in 2025.
  • Quarter analysis of 3 years shows Avidity Biosciences' Treasury Shares stood at $758000.0 in 2023, then surged by 178.5% to $2.1 million in 2024, then increased by 24.59% to $2.6 million in 2025.
  • Its Treasury Shares was $2.6 million in Q1 2025, compared to $2.1 million in Q4 2024 and $1.6 million in Q3 2024.